Hemostemix Inc. (
HEM
) is an innovative-driven publicly-traded biotech company. Its principal business is developing, manufacturing, and commercializing innovative blood-derived stem cell therapies. The company is currently offering a trading volume of 130K+, followed by the 30-day estimated average volume of 240.6K.
HEM